Organogenesis upgraded by BTIG Research with a new price target
$ORGO
Biotechnology: Pharmaceutical Preparations
Health Care
BTIG Research upgraded Organogenesis from Neutral to Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2024 | $5.00 | Buy | Lake Street |
| 2/7/2024 | $5.00 | Overweight | Cantor Fitzgerald |
| 6/15/2023 | $5.00 | Equal-Weight | Morgan Stanley |
| 5/24/2023 | $10.00 | Neutral → Buy | BTIG Research |
| 11/10/2022 | Buy → Neutral | BTIG Research | |
| 8/10/2022 | Outperform → Perform | Oppenheimer | |
| 11/10/2021 | $26.00 → $20.00 | Outperform | SVB Leerink |
| 8/10/2021 | $24.00 → $25.00 | Outperform | Credit Suisse |
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a
CANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, commends today's decision by the U.S. Centers for Medicare & Medicaid Services (CMS) on local coverage determination (LCD) based on peer-reviewed and evidence-based data of clinical efficacy. The LCD covers skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) in the Medicare population and is now set to become effective on
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Summary: Net revenue of $115.2 million for the third quarter of 2024, an increase of $6.6 million compared to net revenue of $108.5 million for the third quarter of 2023. Net revenue for the third quarter of 2024 consists of: Net revenue from Advanced Wound Care products of $108.0 million, an
Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00
Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00
Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00
SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)
SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)
SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)
8-K - Organogenesis Holdings Inc. (0001661181) (Filer)
8-K - Organogenesis Holdings Inc. (0001661181) (Filer)
10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Summary: Net revenue of $115.2 million for the third quarter of 2024, an increase of $6.6 million compared to net revenue of $108.5 million for the third quarter of 2023. Net revenue for the third quarter of 2024 consists of: Net revenue from Advanced Wound Care products of $108.0 million, an
CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th. Management will host a conference call at 5:00 p.m. Eastern Time on November 12th to discuss the results of the quarter and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the
CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Summary: Net revenue of $130.2 million for the second quarter of 2024, an increase of $12.9 million compared to net revenue of $117.3 million for the second quarter of 2023. Net revenue for the second quarter of 2024 consists of: Net revenue from Advanced Wound Care products of $123.2 million, an
3 - Organogenesis Holdings Inc. (0001661181) (Issuer)
3 - Organogenesis Holdings Inc. (0001661181) (Issuer)
4 - Organogenesis Holdings Inc. (0001661181) (Issuer)
Lake Street analyst Brooks O'Neil initiates coverage on Organogenesis Hldgs (NASDAQ:ORGO) with a Buy rating and announces Price Target of $5.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Gainers Novavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today. Portage Biotech (NASDAQ:PRTG) stock increased by 57.97% to $0.41. The market value of their outstanding shares is at $8.1 million. ITeos Therapeutics (NASDAQ:ITOS) stock rose 46.92% to $17.91. The company's market cap stands at $644.1 million. As per the press release, Q1 earnings came out today. Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 37.87% to $5.25. The company's market cap stands at $86.1 million. As per the press release, Q1 earnings came out yesterday. Cardio Diag
CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a
CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the
Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me